title: The effect of somatostatin, ulinastatin and Salvia miltiorrhiza on severe acute pancreatitis treatment.
abstract: BACKGROUND
  The aim of this study was to evaluate the efficacy of somatostatin, ulinastatin and Salvia miltiorrhiza for treatment of severe acute pancreatitis.
  
  
  METHODS
  Three hundred six patients with severe acute pancreatitis were divided randomly into 5 groups: basic treatment, somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza. Amount of time for resolution of abdominal pain/distention, recovery to normal heart and respiratory rates, amylase and blood glucose levels, Acute Physiology and Chronic Health Evaluation II scores, and levels of tumor necrosis factor-α, interleukin (IL)-6, and IL-10 were analyzed and recorded for all 5 subgroups.
  
  
  RESULTS
  Tumor necrosis factor-α and IL-6 levels on the fourth and seventh days, and Acute Physiology and Chronic Health Evaluation II scores on the seventh day after treatment showed significant decrease in the somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. IL-10 levels on the fourth and seventh days were significantly improved in the somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. The incidences of pancreatic sepsis, multiple organ dysfunction syndrome and mortality were lower in the somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup.
  
  
  CONCLUSIONS
  Somatostatin is effective for the treatment of acute pancreatitis and both ulinastatin and S miltiorrhiza demonstrate improvement in therapeutic benefits.
authors.affiliation: Department of Digestive Internal Medicine (GW, JW, PW), Nanfang Medical University Pingxiang Hospital, Pingxiang, China; Department of Pharmaceutical Sciences (RRW, S-FZ), College of Pharmacy, University of South Florida, Tampa, Florida; Laboratory of Shock (XX), Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, China.
authors.forename: Guiliang
authors.initials: G
authors.lastname: Wang
authors.forename: Jianbo
authors.initials: J
authors.lastname: Wen
authors.forename: Rhonda R
authors.initials: RR
authors.lastname: Wilbur
authors.forename: Ping
authors.initials: P
authors.lastname: Wen
authors.forename: Shu-Feng
authors.initials: SF
authors.lastname: Zhou
authors.forename: Xianzhong
authors.initials: X
authors.lastname: Xiao
mesh_terms: D018806:APACHE; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D019283:Pancreatitis, Acute Necrotizing / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D011446:Prospective Studies; D027561:Salvia miltiorrhiza; D012720:Severity of Illness Index; D013004:Somatostatin / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
chemical_list: D006023:Glycoproteins; D015850:Interleukin-6; D028321:Plant Preparations; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D013004:Somatostatin; C028665:urinastatin